CG 0070

Drug Profile

CG 0070

Alternative Names: CG0070

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cold Genesys
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer

Most Recent Events

  • 21 Sep 2017 CG 0070 is still in phase II/III trials for Bladder cancer in USA
  • 15 May 2017 Interim efficacy data from a phase II trial in Bladder cancer presented at the 112th Annual Meeting of the American Urological Association (AUA-2017)
  • 03 Apr 2017 Cold Genesys completes enrolment in its phase II trial for Bladder cancer (Second-line therapy or greater) in USA (NCT02365818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top